Tag: Regeneron
Regeneron accused of fraud by the Department of Justice – 04/11/2024 at 2:36 p.m.
(AOF) – The US Department of Justice announced on Wednesday that it had filed a complaint under the False Claims Act (FCA) against the company Regeneron, as manufacturer of the…
Regeneron: Adjusted EPS down 6% in the 4th quarter
(CercleFinance.com) – Regeneron publishes revenue of $3.43 billion for the 4th quarter of 2023, up 1% compared to the same period a year earlier. Adjusted net profit was down 6%,…
Regeneron: in red, a broker lowers its recommendation
(CercleFinance.com) – Regeneron sheds more than 3% in New York as Canaccord Genuity today downgraded its recommendation on the stock from ‘buy’ to ‘hold’ and adjusted its price target from…
Regeneron: the FDA approves the use of Evkeeza for children aged 5 to 11 – 03/22/2023 at 13:52
(AOF) – The American laboratory Regeneron announces that the FDA, the American authority in charge of health products, extends the authorization of its product Evkeeza to children aged 5 to…
Regeneron: profits relapse
By Jean-Noel Legalland Published on 02/03/2023 at 1:24 p.m. Photo credit © ENG Pictures (Boursier.com) — Regenerate…
Regeneron: adjusted net profit down 28% in the 3rd quarter
(CercleFinance.com) – Regeneron Pharmaceuticals publishes sales of $2.93 billion for the third quarter of 2022, down 15% compared to the same period a year earlier. Adjusted net profit was $1,270…
Regeneron: Jefferies initiates underperforming follow-up
(CercleFinance.com) – Jefferies is initiating a follow-up on Regeneron with an ‘underperforming’ opinion and a price target of $536, considering that the competitive environment will make it difficult for the…
Sanofi: Libtayo rights transferred to Regeneron
Read also (CercleFinance.com) – Sanofi announced on Thursday that it had sold its American partner Regeneron the exclusive licensing rights to the cancer drug Libtayo on a global scale. Under…
Sanofi sells Libtayo licensing rights to Regeneron for $900m
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced Thursday that it has sold its American partner Regeneron the exclusive licensing rights to Libtayo worldwide, for an initial amount of 900 million…
Sanofi restructures its partnership with Regeneron in immuno-oncology
Sanofi restructures its partnership with Regeneron in immuno-oncology | Photo credits: (c) Sanofi Pasteur PARIS, June 2 (Reuters) – Sanofi announced on Thursday a restructuring of its collaboration with Regeneron…
Sanofi sells rights to cancer drug to Regeneron for $900 million
Since 2015, the two laboratories have shared equally the operating profits generated by the sales of this drug worldwide. The American laboratory Regeneron will pay at least 900 million dollars…
Sanofi: Libtayo rights sold to Regeneron
Sanofi announced Thursday that it has ceded its American partner Regeneron the exclusive licensing rights to the cancer drug Libtayo on a global scale. Under the terms of the agreement,…